FCGR2A and nonpapillary renal cell carcinoma: Our analysis of 876 ccRCC specimens and obesity-associated transcriptomes reveals FCGR2A as a central regulator of immune-metabolic crosstalk, establishing novel diagnostic biomarkers and therapeutic targets.